Sanofi SA vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.16 (market cap $3.80B). The key difference: Sanofi SA is far larger — about 25× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and Sanofi SA pays a 6.01% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| SNY | VNQI | |
|---|---|---|
Market Cap | $95.18B | $3.80B |
Volume | 2,995,646 | 277,049 |
Sector | Health | — |
52-Week High | $52.34 | $50.76 |
52-Week Low | $39.51 | $41.81 |
Typical Hold Time | 94 Days | 95 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $42.08, up 0.63% with bearish technical signals from moving averages. The ETF provides international real estate exposure across 30+ countries, offering a higher dividend yield than domestic alternatives. Recent news highlights a significant 45.9% drop in short interest in September 2026, while technical indicators show oversold conditions with RSI readings below 30.
The ETF faces headwinds from global real estate market volatility but offers diversification benefits and income potential. Key risks include international currency exposure and regional economic uncertainties. The substantial decline in short interest suggests potential sentiment improvement, though technical trends remain bearish near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →